Aquestive Therapeutics Reports Widened Losses, Anaphylm FDA Approval Delayed to Mid-2027, Libervant Market Access Vacated

summarizeSummary

Aquestive Therapeutics reported a significant increase in net loss for 2025, alongside a major FDA approval delay for its key drug candidate Anaphylm and the vacating of market access for Libervant due to a legal ruling.

check_boxKey Events

• Financial Performance Deteriorates

  Net loss widened to $83.8 million in 2025 from $44.1 million in 2024, with total revenues decreasing by 23% year-over-year to $44.5 million.

• Anaphylm FDA Approval Delayed

  The FDA issued a Complete Response Letter (CRL) for Anaphylm on January 30, 2026, citing deficiencies in the Human Factors validation study. This delays resubmission to Q3 2026 and potential approval to mid-2027. The CRL did not question clinical trial results or CMC issues.

• Libervant Market Access Vacated by Court

  A court ruling on February 14, 2025, vacated FDA approval for Libervant for ARS patients aged 2-5 years due to orphan drug exclusivity, leading the company to cease marketing activities. An appeal is ongoing, with new legislation potentially impacting the outcome.

• RTW Financing and Anaphylm Deadline Extension

  On March 3, 2026, the company secured a $5.0 million equity commitment and issued warrants to RTW, concurrently extending the Anaphylm Marketing Approval Deadline to June 30, 2027.

auto_awesomeAnalysis

Aquestive Therapeutics faces significant headwinds following a challenging 2025 and early 2026. The substantial increase in net loss and the 23% revenue decline underscore operational difficulties. The FDA's Complete Response Letter for Anaphylm, a critical pipeline asset, is a major setback, pushing its potential approval and commercialization further into 2027. While the CRL focused on human factors rather than clinical efficacy or manufacturing, the need for additional studies introduces further delays and costs. Concurrently, the court's decision to vacate Libervant's FDA approval for a key pediatric population eliminates a near-term revenue stream and adds legal uncertainty, despite new legislation that could potentially aid the appeal. The auditor's explicit mention of a "going concern" issue, coupled with the need for substantial additional capital before principal debt payments begin in June 2026, highlights severe liquidity risks. The recent $5.0 million equity commitment from RTW is a modest capital injection against these significant financial and regulatory challenges. Investors should be prepared for continued volatility and a prolonged path to profitability, heavily dependent on successful Anaphylm resubmission and favorable resolution of the Libervant legal battle.